CDKN2A and cancer: In summary, epigenetic regulation by DNA methylation (e.g., CDKN2A) could represent a key driver affecting the nerve–cancer crosstalk leading to PNI in HNSCC and serve as a promising drug target for therapeutic intervention in the cancer dissemination via nerve tracks [51].